Allmänna diskussioner

While early success was found in blood cancers, 2026 marks the breakthrough of CD47 therapy in Solid Tumors, such as gastric, head and neck, and lung cancers. The challenge with solid tumors is the "cold" tumor microenvironment, which is often devoid of active immune cells.

To address this, the industry has pivoted toward Bispecific Antibodies. These "dual-targeting" molecules bind to CD47 and a tumor-specific antigen (such as HER2, CD20, or DLL3) simultaneously.

• Enhanced Selectivity: By requiring two "anchors" to bind firmly, these bispecifics (like PT217) only activate the immune response in the immediate vicinity of the tumor, sparing healthy systemic tissues.

• Localized Activation: This approach effectively "drags" macrophages directly into the tumor mass. Once there, the CD47 blockade allows them to begin the destruction of the solid tumor from the inside out. In 2026, these agents are showing particular promise in treating Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and gastroesophageal junction cancers.

While HRT is the gold standard for efficacy, 2026 has introduced a robust "dual-track" system for women who cannot or choose not to use hormones (e.g., breast cancer survivors).

• Neurokinin-3 (NK3) Antagonists: Non-hormonal drugs like Fezolinetant and Elinzanetant are now widely available. They target the thermoregulatory center in the brain to "switch off" hot flashes without affecting estrogen receptors.

• GSM Guidelines: New 2025-2026 guidelines for Genitourinary Syndrome of Menopause (GSM) provide evidence-based pathways for using local ultra-low-dose estrogen to treat vaginal atrophy and recurring UTIs, often safe even for those with a history of certain cancers.

• PCOS and Metabolic Health: HRT protocols in 2026 have expanded to include specialized "Metabolic Synchronization" for women with PCOS, using hormone therapy to mitigate insulin resistance and long-term diabetic risks.

taly hosts one of the oldest and most prestigious gatherings in the field: the Laser Florence Congress. Entering its 31st edition in 2026, this congress serves as a vital platform for Italian and international researchers to discuss the future of laser medicine.

The focus in 2026 has shifted toward Photobiomodulation (PBM) and Low-Level Laser Therapy (LLLT). Unlike high-power surgical lasers, PBM uses low-intensity light to stimulate cellular repair and reduce inflammation. Italian clinics are increasingly adopting PBM for pain management, wound healing in diabetic patients, and even neurological rehabilitation, emphasizing the "biostimulatory" potential of light over its destructive capabilities.

The most significant advancement in 2026 is the role of AI as a virtual diagnostic partner within the CBCT workflow. In the US, digital penetration in dental clinics is high, with a significant portion of institutions utilizing AI-integrated imaging technologies to improve diagnostic speed and accuracy.

AI algorithms have reached high levels of accuracy in anatomical segmentation, allowing for automated nerve canal mapping, bone density assessment, and sinus boundary identification. This automation has substantially reduced diagnostic interpretation time. Furthermore, machine learning modules now flag periapical lesions, vertical root fractures, and soft-tissue calcifications that might be missed by the human eye, improving early diagnosis rates for hard-tissue pathologies.